Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by r0naldon Jun 09, 2020 2:36pm

62 Views

Post# 31129863

RE:RE:Personal attacks

Thank you for your kind response. Appreciate it! Lol. I probably know more about Cipher than you think, not that it's important.
Share buy backs are not about outstanding shares, but all about having more liquidity than needed. In my opinion Cipher is very much undervalued. So much that it would not make sense to use excess liquidity for any other purpose then to buy back shares.
For your information I specifically asked this question as the CEO when asked if he would consider paying dividends he responded he did not want to do that.
Maybe you can ask more relevant questions to our CEO and share? Thank you.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec